Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Oligodendrocyte precursor cell differentiation refers to the biological process by which oligodendrocyte precursor cells (OPCs) mature into fully functional oligodendrocytes capable of producing myelin in the central nervous system. This process is tightly regulated by a network of transcription factors—including Sox10, Olig2, Nkx2.2—and chromatin remodelers such as Chd7 and Chd8 that orchestrate stage-specific gene expression changes necessary for lineage progression and myelination[1]. Differentiation is influenced by both intrinsic genetic programs and extrinsic environmental cues; astrocyte-derived bone morphogenetic proteins inhibit OPC maturation while chemokine signaling can promote proliferation but restrict migration[3][6]. Disruption in OPC differentiation contributes to diseases like multiple sclerosis due to failed remyelination or certain brain tumors where developmental programs are dysregulated[4][2]. While not itself a druggable molecular target—rather a cellular process—understanding its regulation provides therapeutic entry points for enhancing remyelination or modulating glial responses in neurological disorders. **Note:** "Oligodendrocyte precursor cell differentiation" describes a *process*, not a discrete molecule/receptor/protein. It should not be considered a canonical therapeutic target per se but rather an important biological event governed by several molecular targets within the pathway. If structured data are required for drug discovery purposes, focus should shift toward individual regulators within this process such as PDGFRα receptor, SOX10 transcription factor, or CHD family chromatin remodelers.
Modulation of transcription factors such as Sox10, Olig2, Nkx2.2[1]; Chromatin remodeling via CHD family proteins (Chd7/Chd8)[1]; Inhibition or promotion by extracellular signals including bone morphogenetic proteins (BMPs), chemokines like CXCL1/CXCR2 axis[3], and cytokines such as IFN-gamma[7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Oligodendrocyte precursor cell differentiation.